Ströbel, Philipp

[["dc.bibliographiccitation.firstpage","738"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Genes Chromosomes and Cancer"],["dc.bibliographiccitation.lastpage","749"],["dc.bibliographiccitation.volume","53"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Zettl, Andreas"],["dc.contributor.author","Shilo, Konstantin"],["dc.contributor.author","Chuang, Wen-Yu"],["dc.contributor.author","Nicholson, Andrew G."],["dc.contributor.author","Matsuno, Yoshihiro"],["dc.contributor.author","Gal, Anthony"],["dc.contributor.author","Laeng, Rolf Hubert"],["dc.contributor.author","Engel, Peter"],["dc.contributor.author","Capella, Carlo"],["dc.contributor.author","Marino, Mirella"],["dc.contributor.author","Chan, John Kwok-Cheung"],["dc.contributor.author","Rosenwald, Andreas"],["dc.contributor.author","Travis, William D."],["dc.contributor.author","Franks, Teri J."],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Marx, Alexander"],["dc.date.accessioned","2018-11-07T09:36:21Z"],["dc.date.available","2018-11-07T09:36:21Z"],["dc.date.issued","2014"],["dc.description.abstract","Thymic neuroendocrine tumors (TNET) are rare primary epithelial neoplasms of the thymus. This study aimed to determine clinically relevant parameters for their classification and for therapeutic decisions. We performed a comprehensive histological, clinical, and genetic study of 73 TNET cases (13 thymic typical carcinoids [TTC], 40 thymic atypical carcinoids [TAC], and 20 high-grade neuroendocrine carcinomas [HGNEC] of the thymus), contributed by multiple institutions. The mean number of chromosomal imbalances per tumor was 0.8 in TTC (31% aberrant cases) versus 1.1 in TAC (44% aberrant cases) versus 4.7 in HGNEC (75% aberrant cases). Gains of 8q24 (MYC gene locus) were the most frequent alteration and one of the overlapping features between carcinoids and HGNEC. The 5-year survival rates for TTC, TAC, and HGNEC were 100, 60, and 30%. The 10-year survival rates for TTC and TAC were 50 and 30% (P=0.002). Predictive mitotic cut-off values for TTC versus TAC were 2.5 per 10 high-power fields (HPF; indicating a higher death rate, P=0.062) and 15 per 10 HPF (indicating higher risk of recurrence, P=0.036) for separating HGNEC from TAC. We conclude that the current histopathologic classifications of TNET reflect tumor biology and provide important information for therapeutic management. (C) 2014 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/gcc.22183"],["dc.identifier.isi","000339670200003"],["dc.identifier.pmid","24764238"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32598"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1098-2264"],["dc.relation.issn","1045-2257"],["dc.title","Tumor Genetics and Survival of Thymic Neuroendocrine Neoplasms: A Multi-Institutional Clinicopathologic Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","894"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY"],["dc.bibliographiccitation.lastpage","905"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Belharazem, Djeda"],["dc.contributor.author","Schalke, Berthold"],["dc.contributor.author","Gold, Ralf"],["dc.contributor.author","Nix, Wilfred"],["dc.contributor.author","Vitacolonna, Mario"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Roessner, Eric"],["dc.contributor.author","Schulze, Torsten J."],["dc.contributor.author","Saruhan-Direskeneli, Gueher"],["dc.contributor.author","Yilmaz, Vuslat"],["dc.contributor.author","Ott, German"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Marx, Alexander"],["dc.date.accessioned","2018-11-07T09:51:57Z"],["dc.date.available","2018-11-07T09:51:57Z"],["dc.date.issued","2015"],["dc.description.abstract","Objective: The capacity of thymomas to generate mature CD4+ effector T cells from immature precursors inside the tumor and export them to the blood is associated with thymoma-associated myasthenia gravis (TAMG). Why TAMG (+) thymomas generate and export more mature CD4+ T cells than MG(-) thymomas is unknown. Methods: Unfixed thymoma tissue, thymocytes derived thereof, peripheral blood mononuclear cells (PBMCs), T-cell subsets and B cells were analysed using qRT-PCR and western blotting. Survival of PBMCs was measured by MTT assay. FAS-mediated apoptosis in PBMCs was quantified by flow cytometry. NF-kappa B in PBMCs was inhibited by the NF-kappa B-Inhibitor, EF24 prior to FAS-Ligand (FASLG) treatment for apoptosis induction. Results: Expression levels of the apoptosis inhibitor cellular FLICE-like inhibitory protein (c-FLIP) in blood T cells and intratumorous thymocytes were higher in TAMG(+) than in MG(-) thymomas and non-neoplastic thymic remnants. Thymocytes and PBMCs of TAMG patients showed nuclear NF-kappa B accumulation and apoptosis resistance to FASLG stimulation that was sensitive to NF-kappa B blockade. Thymoma removal reduced cFLIP expression in PBMCs. Interpretation: We conclude that thymomas induce cFLIP overexpression in thymocytes and their progeny, blood T cells. We suggest that the stronger cFLIP overexpression in TAMG(+) compared to MG(-) thymomas allows for the more efficient generation of mature CD4+ T cells in TAMG(+) thymomas. cFLIP overexpression in thymocytes and exported CD4+ T cells of patients with TAMG might contribute to the pathogenesis of TAMG by impairing central and peripheral T-cell tolerance."],["dc.identifier.doi","10.1002/acn3.210"],["dc.identifier.isi","000367238200003"],["dc.identifier.pmid","26401511"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36014"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","2328-9503"],["dc.title","cFLIP overexpression in T cells in thymoma-associated myasthenia gravis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","361"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Tumori Journal"],["dc.bibliographiccitation.lastpage","368"],["dc.bibliographiccitation.volume","104"],["dc.contributor.author","Ronellenfitsch, Ulrich"],["dc.contributor.author","Ernst, Kristina"],["dc.contributor.author","Mertens, Christina"],["dc.contributor.author","Trunk, Marcus J."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Kienle, Peter"],["dc.contributor.author","Post, Stefan"],["dc.contributor.author","Nowak, Kai"],["dc.date.accessioned","2020-12-10T18:38:25Z"],["dc.date.available","2020-12-10T18:38:25Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1177/0300891618792485"],["dc.identifier.eissn","2038-2529"],["dc.identifier.issn","0300-8916"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77310"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Extensive intraperitoneal lavage to eliminate intraperitoneal tumor cells in gastrectomy with D2 lymphadenectomy for gastric cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e0197435"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Weis, Cleo-Aron"],["dc.contributor.author","Aban, Inmaculada B."],["dc.contributor.author","Cutter, Garry"],["dc.contributor.author","Kaminski, Henry J."],["dc.contributor.author","Scharff, Christoph"],["dc.contributor.author","Grießmann, Benedict W."],["dc.contributor.author","Deligianni, Maria"],["dc.contributor.author","Kayser, Klaus"],["dc.contributor.author","Wolfe, Gil I."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.editor","Phillips, William D."],["dc.date.accessioned","2020-12-10T18:42:07Z"],["dc.date.available","2020-12-10T18:42:07Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1371/journal.pone.0197435"],["dc.identifier.eissn","1932-6203"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77812"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","704"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Histopathology"],["dc.bibliographiccitation.lastpage","710"],["dc.bibliographiccitation.volume","70"],["dc.contributor.author","Buerger, Tobias"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Kueffer, Stefan"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Reuter-Jessen, Kirsten"],["dc.contributor.author","Chan, John Kwok-Cheung"],["dc.contributor.author","Emmert, Alexander"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Stroebel, Philipp"],["dc.date.accessioned","2018-11-07T10:25:44Z"],["dc.date.available","2018-11-07T10:25:44Z"],["dc.date.issued","2017"],["dc.description.abstract","AimsThe vast majority of type A thymomas are diagnosed in tumour stages 1 or 2, and metastatic cases are exceedingly rare. The histological and genetic features of such metastatic type A thymomas have not been described in detail. Methods and resultsFive metastatic type A thymomas in tumour stage Masaoka IVb that had been reviewed by a panel of expert pathologists were analysed using comparative genomic hybridization (CGH). Cases 1, 2 and 3 showed the prototypical morphology of type A thymomas with mainly solid growth patterns. These cases displayed only very subtle nuclear irregularities and slight nuclear crowding, but no other atypical features. Mitoses were absent. Cases 3 and 4, in contrast, had a distinctly atypical morphology. CGH revealed partially recurrent alterations in four cases (with and without atypical morphology), including gains on chromosome 1q (one case), 17q (two cases), chromosome 19 (three cases) and 22q (one case) and losses on chromosome 17p (two cases) and 22q (one case). ConclusionRare metastatic type A thymomas, both with typical and atypical' histological features, show partially recurrent genomic alterations that differ from the much more frequent localized and indolent tumours. The fact that these alterations were recurring points to a link between clinical behaviour and molecular features. Our findings may have implications for the management and treatment of such tumours."],["dc.identifier.doi","10.1111/his.13138"],["dc.identifier.isi","000397588600003"],["dc.identifier.pmid","27926794"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42916"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.relation.issn","1365-2559"],["dc.relation.issn","0309-0167"],["dc.title","Metastatic type A thymoma: morphological and genetic correlation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","ENDOCRINE CONNECTIONS"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Belharazem, Djeda"],["dc.contributor.author","Kirchner, Matthias"],["dc.contributor.author","Geissler, Franziska"],["dc.contributor.author","Bugert, Peter"],["dc.contributor.author","Spahn, Martin"],["dc.contributor.author","Kneitz, Burkhard"],["dc.contributor.author","Riedmiller, Hubertus"],["dc.contributor.author","Sauer, Christian"],["dc.contributor.author","Kueffer, Stefan"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Michel, Maurice Stephan"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Stroebel, Philipp"],["dc.date.accessioned","2018-11-07T09:04:21Z"],["dc.date.available","2018-11-07T09:04:21Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: Insulin-like growth factor 2 (IGF2) is the predominant IGF in adults and regulates cell growth. In contrast to normal tissues, where IGF2 is imprinted and only expressed from the paternal allele, loss of imprinting (LOI) and biallelic IGF2 expression are observed in many cancers including prostate cancer (PCa). We here studied whether LOI of IGF2 in normal circulating peripheral blood lymphocytes can predict increased PCa risk. Samples and methods: We analyzed IGF2 protein levels, IGF2 820G/A genotype and imprinting status, as well as methylation status of the IGF2 imprinting control region (ICR) in 113 blood samples of patients with a history of radical prostatectomy (RPE) for PCa by ELISA, restriction-fragment length polymorphism, and bisulfite-DNA sequencing. Results were compared to 249 male blood donors with unknown prostate specific antigen (PSA) status. Results: The 820G/A genotype was enriched in the RPE group and was associated with younger age at cancer diagnosis. LOI in patients was only slightly more frequent than in controls, but IGF2 levels were significantly higher and uncoupled from the imprinting status. Analysis of the IGF2/H19 ICR revealed marked hypermethylation. Conclusions: The IGF 820G/A genotype is associated with PCa diagnosis at younger age. Increased IGF2 in patients with PCa appears to be the result of impaired imprinting in non-neoplastic cells rather than a paracrine tumor product. Uncoupling of IGF2 protein levels from imprinting status (not LOI alone) and hypermethylation of the ICR characterized PCa patients and could have the potential to indicate persons at risk in screening programs."],["dc.identifier.doi","10.1530/EC-12-0054"],["dc.identifier.isi","000209773300005"],["dc.identifier.pmid","23781309"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25099"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bioscientifica Ltd"],["dc.relation.issn","2049-3614"],["dc.title","Relaxed imprinting of IGF2 in peripheral blood cells of patients with a history of prostate cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","323"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Virchows Archiv"],["dc.bibliographiccitation.lastpage","327"],["dc.bibliographiccitation.volume","476"],["dc.contributor.author","Porubsky, Stefan"],["dc.contributor.author","Jessup, Peter"],["dc.contributor.author","Kee, Damien"],["dc.contributor.author","Sharma, Rajiv"],["dc.contributor.author","Ochi, Ayame"],["dc.contributor.author","Xu, Huiling"],["dc.contributor.author","Froelich, Jens J."],["dc.contributor.author","Nott, Louise"],["dc.contributor.author","Scott, Clare"],["dc.contributor.author","Awad, Raef"],["dc.contributor.author","Moldovan, Cristina"],["dc.contributor.author","Hardikar, Ashutosh A."],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Küffer, Stefan"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Marx, Alexander"],["dc.date.accessioned","2020-12-10T14:10:36Z"],["dc.date.available","2020-12-10T14:10:36Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00428-019-02644-3"],["dc.identifier.eissn","1432-2307"],["dc.identifier.issn","0945-6317"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70816"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","875"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Autoimmunity Reviews"],["dc.bibliographiccitation.lastpage","884"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Pfister, Frederick"],["dc.contributor.author","Schalke, Berthold"],["dc.contributor.author","Saruhan-Direskeneli, Guher"],["dc.contributor.author","Melms, Arthur"],["dc.contributor.author","Stroebel, Philipp"],["dc.date.accessioned","2018-11-07T09:23:02Z"],["dc.date.available","2018-11-07T09:23:02Z"],["dc.date.issued","2013"],["dc.description.abstract","The thymus plays distinct roles in the pathogenesis of the different Myasthenia gravis (MG) subtypes. Inflammatory, neoplastic and age-related alterations of the thymus are of pivotal relevance for the initiation of antiacetylcholine receptor (AChR) autoimmunity in early onset MG, thymoma-associated MG and, likely, late onset MG, respectively. By contrast the thymus is presumably not related to MG that is due to autoantibodies to the muscle specific kinase, MuSK. Finally, the role of the thymus is still obscure in MG defined by antibodies against the agrin receptor LRP4 and in MG without all of the above autoantibdies (triple sero-negative MG) since these MG subtypes have been described only recently and thymectomy has not been their standard treatment This review aims to give an update on intrathymic mechanisms of tolerance breakdown in MG, including abnormal T cell selection and activation, the role of thymic myoid cells, the autoimmune regulator (AIRE) and regulatory T cells. (C) 2013 Elsevier B.V. All rights reserved."],["dc.description.sponsorship","BMBF [01DL12027]; Tubitak"],["dc.identifier.doi","10.1016/j.autrev.2013.03.007"],["dc.identifier.isi","000321411500003"],["dc.identifier.pmid","23535159"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29484"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1568-9972"],["dc.title","The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","82"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Annals of the New York Academy of Sciences"],["dc.bibliographiccitation.lastpage","91"],["dc.bibliographiccitation.volume","1413"],["dc.contributor.author","Weis, Cleo-Aron"],["dc.contributor.author","Schalke, Berthold"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Marx, Alexander"],["dc.date.accessioned","2020-12-10T18:36:19Z"],["dc.date.available","2020-12-10T18:36:19Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/nyas.13563"],["dc.identifier.issn","0077-8923"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76583"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Challenging the current model of early-onset myasthenia gravis pathogenesis in the light of the MGTX trial and histological heterogeneity of thymectomy specimens"],["dc.title.alternative","EOMG pathogenesis and histological heterogeneity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","596"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.lastpage","611"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Badve, Sunil S."],["dc.contributor.author","Chalabreysse, Lara"],["dc.contributor.author","Chan, John Kwok-Cheung"],["dc.contributor.author","Chen, Gang"],["dc.contributor.author","de Leval, Laurence"],["dc.contributor.author","Detterbeck, Frank C."],["dc.contributor.author","Girard, Nicolas"],["dc.contributor.author","Huang, Jim"],["dc.contributor.author","Kurrer, Michael O."],["dc.contributor.author","Lauriola, Libero"],["dc.contributor.author","Marino, Mirella"],["dc.contributor.author","Matsuno, Yoshihiro"],["dc.contributor.author","Molina, Thierry Jo"],["dc.contributor.author","Mukai, Kiyoshi"],["dc.contributor.author","Nicholson, Andrew G."],["dc.contributor.author","Nonaka, Daisuke"],["dc.contributor.author","Rieker, Ralf J."],["dc.contributor.author","Rosai, Juan"],["dc.contributor.author","Ruffini, Enrico"],["dc.contributor.author","Travis, William D."],["dc.date.accessioned","2018-11-07T09:40:58Z"],["dc.date.available","2018-11-07T09:40:58Z"],["dc.date.issued","2014"],["dc.description.abstract","Introduction: The 2004 version of the World Health Organization classification subdivides thymic epithelial tumors into A, AB, B1, B2, and B3 (and rare other) thymomas and thymic carcinomas (TC). Due to a morphological continuum between some thymoma subtypes and some morphological overlap between thymomas and TC, a variable proportion of cases may pose problems in classification, contributing to the poor interobserver reproducibility in some studies. Methods: To overcome this problem, hematoxylin-eosin-stained and immunohistochemically processed sections of prototypic, \"borderland,\" and \"combined\" thymomas and TC (n = 72) were studied by 18 pathologists at an international consensus slide workshop supported by the International Thymic Malignancy Interest Group. Results: Consensus was achieved on refined criteria for decision making at the A/AB borderland, the distinction between B1, B2, and B3 thymomas and the separation of B3 thymomas from TCs. \"Atypical type A thymoma\" is tentatively proposed as a new type A thymoma variant. New reporting strategies for tumors with more than one histological pattern are proposed. Conclusion: These guidelines can set the stage for reproducibility studies and the design of a clinically meaningful grading system for thymic epithelial tumors."],["dc.description.sponsorship","European Society of Pathology"],["dc.identifier.doi","10.1097/JTO.0000000000000154"],["dc.identifier.isi","000334627500005"],["dc.identifier.pmid","24722150"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33619"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1556-1380"],["dc.relation.issn","1556-0864"],["dc.title","ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]